Cancer Center Featured Story 2

Add to Favorites Subscribe Share
fbshare-Cancer Center Featured Story 2
Press "esc" to clear
Go to Advanced Search

Showing results

110 of 1287

Article ID: 708321

Yale Cancer Center researchers combine targeted therapies to fight head and neck cancers

Yale Cancer Center

Yale Cancer Center researchers have identified a potential therapy that combines two types of molecularly targeted drugs to produce a synergistic effect against head and neck cancer.

19-Feb-2019 2:20 PM EST
  • Embargo expired:
    19-Feb-2019 11:00 AM EST

Article ID: 708009

New research shows structural barriers are the biggest reason for low participation in clinical trials

Fred Hutchinson Cancer Research Center

Findings in Journal of the National Cancer Institute shows patients don’t have enough opportunities for participation

19-Feb-2019 11:00 AM EST

Article ID: 708236

Mimicking Metastasis in a Dish

University of Kansas Cancer Center

Researchers at The University of Kansas Cancer Center have developed a first-of-its-kind organoid that mirrors the process of cancer spreading to the lung.

18-Feb-2019 12:05 PM EST
  • Embargo expired:
    18-Feb-2019 12:05 AM EST

Article ID: 708182

Small cell lung cancer may respond to combination of immunotherapy and DNA damage repair inhibitors

University of Texas M. D. Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumor regression in mouse models of small cell lung cancer (SCLC), suggesting a promising new approach for treating patients with this aggressive cancer.

17-Feb-2019 12:05 AM EST
  • Embargo expired:
    16-Feb-2019 5:10 PM EST

Article ID: 708091

Drug combination may become new standard treatment for advanced kidney cancer

Dana-Farber Cancer Institute

A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

15-Feb-2019 2:05 PM EST

Article ID: 708136

Immunotherapy Combination Generates Responses Against Castration-Resistant Metastatic Prostate Cancer

University of Texas M. D. Anderson Cancer Center

Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at MD Anderson

14-Feb-2019 4:05 PM EST

Article ID: 708090

Moffitt Researchers Characterize Mechanism of Action of CAR T Cells

Moffitt Cancer Center

Despite progress being made, scientists have not been completely certain of how CAR T cells function mechanistically. A team of Moffitt Cancer Center researchers addressed this uncertainty and characterized the mechanism of action of these new agents in a new article published this week in Science Signaling.

14-Feb-2019 9:00 AM EST

Article ID: 707957

Lymph Node Removal Procedure as First-Line Treatment for Testicular Seminoma Associated with Favorable Survival Rates

Rutgers Cancer Institute of New Jersey

Investigators at Rutgers Cancer Institute of New Jersey have found that a surgical procedure, when used as a first-line therapy for a form of testicular cancer known as seminoma, is associated with favorable survival rates.

12-Feb-2019 11:05 AM EST
  • Embargo expired:
    11-Feb-2019 5:00 PM EST

Article ID: 707837

Study Finds Upsurge in ‘Active Surveillance’ for Low-Risk Prostate Cancer

Dana-Farber Cancer Institute

Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative “active surveillance” strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute.

11-Feb-2019 8:55 AM EST
  • Embargo expired:
    11-Feb-2019 11:00 AM EST

Article ID: 707800

New therapeutic target found for aggressive pediatric cancers with few treatment options

University of Texas M. D. Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors (MRT), a rare pediatric cancer without effective treatments, may be sensitive to drugs that block the cancer cell’s ability to dispose of misfolded proteins. The findings provide a much-needed therapeutic target for these and other cancers caused by mutations in the SMARCB1 gene.

10-Feb-2019 11:00 AM EST

Showing results

110 of 1287

Chat now!